A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Financial Summary
| Share Statistics | AEON | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $7.7 | $252.6 | 5% |
|
| Shares Out (Mil) | 40.6 | 52.3 | 43% |
|
| Institutional Ownership | 32.9% | 92.1% | 14% |
|
| Float (Mil) | 6.9 | 40.2 | 15% |
|
| Beta | 0.61 | 0.95 | 35% |
|
| Avg Daily Volume (000s) | 1,021 | 455 | 71% |
|
| Price Change (52-week) |
(60.1%) | 52.9% | 12% |
|
| Growth | AEON | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (3.6%) | (9.9%) | 35% |
|
| EPS (5yr) | 62.7% | 16.0% | 96 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (71.2%) | (15.6%) | 2% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | na | |
| Current EPS | ($0.330) | ($1.050) | ($0.520) | |
| Month Ago EPS | ($0.330) | ($1.050) | na | |
| # Rev Up | na | 1 | na | |
| # Rev Down | na | 0 | na | |
| Three Months Ago EPS | ($0.650) | ($1.960) | na | |
| Year/Year Chg | 13.8% | (73.4%) | na | |
| Financials | AEON | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($60) | ($43) | 15% |
|
| EPS (TTM) | ($3.151) | ($1.600) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($31) | 18% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $2 | $5 | 21% |
|
| Enterprise Value (Q1) (Mil) | $4 | $180 | 5% |
|
| Valuation | AEON | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.56 | na |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | AEON | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (536.0%) | (49.8%) | 0% |
|
| ROE | 428.2% | (55.5%) | 99% |
|
| Liabilities to Assets | 294.1% | 30.3% | 99% |
|
| F-Score | 2 | 3 | 7% |
|
AEON Biopharma, Inc. did not pass any screens on 7/31/2026.
